Tuberculosis Prevention and Treatment Vaccine Market

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Gu?rin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
Tuberculosis Prevention and Treatment Vaccine Market contains market size and forecasts of Tuberculosis Prevention and Treatment Vaccine in global, including the following market information:
Global Tuberculosis Prevention and Treatment Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Tuberculosis Prevention and Treatment Vaccine Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Tuberculosis Prevention and Treatment Vaccine companies in 2021 (%)
The global Tuberculosis Prevention and Treatment Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immune Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tuberculosis Prevention and Treatment Vaccine include Merck, Japan BCG Lab, Serum Institute of India, AJ Vaccines, BioFarma, GreenSignal Bio Pharma, China National Biotec, Biomed Lublin and Taj Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tuberculosis Prevention and Treatment Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tuberculosis Prevention and Treatment Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tuberculosis Prevention and Treatment Vaccine Market Segment Percentages, by Type, 2021 (%)
Immune Vaccine
Therapy Vaccine
Global Tuberculosis Prevention and Treatment Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tuberculosis Prevention and Treatment Vaccine Market Segment Percentages, by Application, 2021 (%)
Self-Procurement
UNICEF
Other
Global Tuberculosis Prevention and Treatment Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tuberculosis Prevention and Treatment Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tuberculosis Prevention and Treatment Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Tuberculosis Prevention and Treatment Vaccine revenues share in global market, 2021 (%)
Key companies Tuberculosis Prevention and Treatment Vaccine sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Tuberculosis Prevention and Treatment Vaccine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen